Atlas Trials

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

Clinical trial NCT07283731 · RECRUITING

Trial details

NCT number
NCT07283731
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Phase 2ZanzalintinibPembrolizumabAdvanced/MetastaticSoft-Tissue Sarcoma
Start date
2026-04-14
Primary completion
2028-11-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.